Mike DuVall

Mike DuVall, PhD has a diverse work experience in the field of bioengineering and biotechnology. Mike currently holds the position of Principal Scientist at Edgewise Therapeutics starting from August 2022. Prior to this, they served as a Scientist lll at the same company from May 2021 to August 2022. Mike also worked as a Scientist II at Edgewise Therapeutics from September 2017 to May 2021, where they played a crucial role in establishing the laboratory infrastructure, developing data analysis pipelines, and conducting assay development for drug screening.

In addition to their work at Edgewise Therapeutics, Mike served as an Angel Investor starting from January 2022. Before joining Edgewise Therapeutics, they worked as a Postdoctoral Researcher at the Center for Bioengineering Innovation at Northern Arizona University from August 2015 to September 2017. In this role, they conducted protein and cellular research, managed the Muscle and Motor Control Lab, and developed new technologies for muscle disorder research.

Mike's earlier work experience includes their time as a Graduate Student, PhD at the University of Calgary from September 2009 to August 2015. During this period, they focused on identifying cellular and protein structure/function relationships, developing processes for protein and antibody production, and collaborating with a research team on muscle and joint questions.

Overall, Mike's work experience showcases their expertise in bioengineering, drug development, and muscle disorder research.

Mike DuVall, PhD, completed their education in a chronological order. Mike started their academic journey in 2004 at the University of Calgary, where they pursued a Bachelor of Science (BS) degree in Biological Sciences. Mike attended the university for five years, completing their undergraduate studies in 2009.

Following their bachelor's degree, Mike pursued higher education at the Schulich School of Engineering, also located at the University of Calgary. From 2009 to 2015, they dedicated himself to their doctoral studies in Biomedical Engineering and successfully earned their Doctor of Philosophy (Ph.D.) degree.

In addition to their formal education, Mike DuVall has also obtained several certifications to enhance their skills and knowledge. Some of these certifications include "Angel Investing" from the Angel Capital Association in December 2022, "Venture Deals" from Techstars in March 2022, and various courses from Udemy and LinkedIn on topics such as Python programming, data science, and MATLAB. Additionally, they completed the "GCP for Clinical Trials with Investigational Drugs and Medical Devices (U.S. FDA Focus) Course" from the CITI Program in April 2022.